Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex ... Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites. Mehr anzeigen
Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned...
Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.49 | 3.15077183337 | 47.29 | 48.78 | 45.72 | 454212 | 47.13859274 | CS |
| 4 | -5.35 | -9.883613523 | 54.13 | 57.14 | 43.61 | 783558 | 51.63435188 | CS |
| 12 | 3.84 | 8.54472630174 | 44.94 | 57.14 | 43.2501 | 704223 | 49.7231453 | CS |
| 26 | 21.14 | 76.483357453 | 27.64 | 57.14 | 20.0818 | 734023 | 39.00332883 | CS |
| 52 | 23.24 | 90.9945184025 | 25.54 | 57.14 | 20.0818 | 705815 | 35.83480804 | CS |
| 156 | 31.28 | 178.742857143 | 17.5 | 57.14 | 10.8001 | 398007 | 28.08577368 | CS |
| 260 | 30.48 | 166.557377049 | 18.3 | 63.69 | 10.8001 | 295682 | 28.3118039 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
